Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Align Tech (ALGN) was upgraded to a Buy Rating at Barclays

Tipranks - Tipranks - Wed Mar 18, 2:46AM CDT

Align Tech received a Buy rating and a $200.00 price target from Barclays analyst Glen Santangelo today.

Claim 70% Off TipRanks Premium

Santangelo covers the Healthcare sector, focusing on stocks such as Align Tech, Teva Pharmaceutical, and Cencora. According to TipRanks, Santangelo has an average return of 4.7% and a 50.18% success rate on recommended stocks.

In addition to Barclays, Align Tech also received a Buy from TipRanks – OpenAI’s OpenAI Medical – Devices in a report issued yesterday. However, on the same day, TipRanks – PerPlexity reiterated a Hold rating on Align Tech (NASDAQ: ALGN).

See the top stocks recommended by analysts >>

Based on Align Tech’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.05 billion and a net profit of $135.76 million. In comparison, last year the company earned a revenue of $995.22 million and had a net profit of $103.81 million

Read More on ALGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).